095700.KQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 02:30):

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea...

Stats
Today's Volume	75 300.00
Average Volume	226 828
Market Cap	304.66B
EPS	KRW0 ( 2024-02-08 )
Next earnings date	( KRW229.00 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW17.34 (0.24%)

Volume Correlation

Long: -0.07 (neutral)

Short: -0.57 (weak negative)

Signal:(51.82) Neutral

Genexine, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genexine, Inc. Correlation - Currency/Commodity

0.38
( neutral )

0.27
( neutral )

0.20
( neutral )

0.01
( neutral )

0.26
( neutral )

0.25
( neutral )

Genexine, Inc. Financials

Annual	2023
Revenue:	KRW4.43B
Gross Profit:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

Q4	2023
Revenue:	KRW1.53B
Gross Profit:	KRW-915.29M (-59.64 %)
EPS:	KRW62.48

Q3	2023
Revenue:	KRW368.52M
Gross Profit:	KRW-1.25B (-338.81 %)
EPS:	KRW-505.07

Q2	2023
Revenue:	KRW1.83B
Gross Profit:	KRW-889.28M (-48.55 %)
EPS:	KRW-603.06

Financial Reports:

No articles found.

Genexine, Inc.

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.